Can you take Esketamine with Methoxyflurane?
1 drug interaction and 10 additional warnings found for the following 2 drugs:
- esketamine
- methoxyflurane
Drug interactions
Major drug interactions
Major:
methoxyflurane esketamine
Applies to: methoxyflurane and esketamine
Using esketamine together with methoxyflurane may increase side effects such as:
- drowsiness
- confusion
- difficulty concentrating
- impairment in thinking, judgment, reaction speed, and motor coordination
After receiving treatment with esketamine, you should avoid driving or operating hazardous machinery until the next day after a restful sleep.
Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
esketamine Food/Lifestyle
Applies to: esketamine
Using esketamine together with alcohol may increase side effects such as:
- drowsiness
- confusion
- difficulty concentrating
- impairment in thinking, judgment, reaction speed, and motor coordination
You should avoid or limit the use of alcohol while being treated with esketamine.
Nausea and vomiting may occur following the nasal application of esketamine.
To help prevent nausea and vomiting, you should avoid eating for at least 2 hours before using esketamine and avoid drinking liquids for at least 30 minutes before using esketamine.
Moderate:
methoxyflurane Alcohol (Ethanol)
Applies to: methoxyflurane
Using methoxyflurane together with ethanol (alcohol) may increase side effects such as:
- dizziness
- drowsiness
- confusion
- difficulty concentrating
Some people may also experience impairment in thinking, judgment, and motor coordination.
You should avoid or limit the use of alcohol while being treated with methoxyflurane.
Do not use more than the recommended dose of methoxyflurane, and avoid driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until you know how the medication affects you.
Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
8 potential interactions Applies to: 8 conditions, including High Blood Pressure, Allergies, Psychosis, Aortic Aneurysm, and Drug Dependence.
Allergies
Major:
esketamine
Esketamine has a major potential interaction with Allergies.
Esketamine causes an increase in systolic and/or diastolic blood pressure at all recommended doses. The increase peaks approximately 40 minutes after administration of esketamine, and lasts for about 4 hours. Blood pressure should be monitored prior and after administration. If baseline blood pressure is elevated before administering (e.g., >140 mmHg systolic, >90 mmHg diastolic), consider the risks of short term increases in blood pressure and benefit of treatment in patients with treatment- resistant depression (TRD). Do not administer esketamine if an increase in blood pressure or intracranial pressure poses a serious risk. Esketamine is contraindicated in patients with aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels), arteriovenous malformations, or a history of intracerebral hemorrhage.
Aortic Aneurysm
Major:
esketamine
Esketamine has a major potential interaction with Aortic Aneurysm.
Esketamine causes an increase in systolic and/or diastolic blood pressure at all recommended doses. The increase peaks approximately 40 minutes after administration of esketamine, and lasts for about 4 hours. Blood pressure should be monitored prior and after administration. If baseline blood pressure is elevated before administering (e.g., >140 mmHg systolic, >90 mmHg diastolic), consider the risks of short term increases in blood pressure and benefit of treatment in patients with treatment- resistant depression (TRD). Do not administer esketamine if an increase in blood pressure or intracranial pressure poses a serious risk. Esketamine is contraindicated in patients with aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels), arteriovenous malformations, or a history of intracerebral hemorrhage.
Cerebral Vascular Disorder
Major:
esketamine
Esketamine has a major potential interaction with Cerebral Vascular Disorder.
Esketamine causes an increase in systolic and/or diastolic blood pressure at all recommended doses. The increase peaks approximately 40 minutes after administration of esketamine, and lasts for about 4 hours. Blood pressure should be monitored prior and after administration. If baseline blood pressure is elevated before administering (e.g., >140 mmHg systolic, >90 mmHg diastolic), consider the risks of short term increases in blood pressure and benefit of treatment in patients with treatment- resistant depression (TRD). Do not administer esketamine if an increase in blood pressure or intracranial pressure poses a serious risk. Esketamine is contraindicated in patients with aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels), arteriovenous malformations, or a history of intracerebral hemorrhage.
Drug Dependence
Major:
esketamine
Esketamine has a major potential interaction with Drug Dependence.
Esketamine, is a Schedule III controlled substance (CIII), and may be subject to abuse and diversion. Assess each patient's risk for abuse or misuse prior to prescribing esketamine and monitor all patients receiving treatment for the development of these behaviors or conditions, including drug- seeking behavior, while on therapy. Individuals with a history of drug abuse or dependence are at greater risk; therefore, use careful consideration prior to treatment of individuals with a history of substance use disorder and monitor for signs of abuse or dependence.
High Blood Pressure
Major:
esketamine
Esketamine has a major potential interaction with High Blood Pressure.
Esketamine causes an increase in systolic and/or diastolic blood pressure at all recommended doses. The increase peaks approximately 40 minutes after administration of esketamine, and lasts for about 4 hours. Blood pressure should be monitored prior and after administration. If baseline blood pressure is elevated before administering (e.g., >140 mmHg systolic, >90 mmHg diastolic), consider the risks of short term increases in blood pressure and benefit of treatment in patients with treatment- resistant depression (TRD). Do not administer esketamine if an increase in blood pressure or intracranial pressure poses a serious risk. Esketamine is contraindicated in patients with aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels), arteriovenous malformations, or a history of intracerebral hemorrhage.
History - Cerebrovascular Disease
Major:
esketamine
Esketamine has a major potential interaction with History - Cerebrovascular Disease.
Esketamine causes an increase in systolic and/or diastolic blood pressure at all recommended doses. The increase peaks approximately 40 minutes after administration of esketamine, and lasts for about 4 hours. Blood pressure should be monitored prior and after administration. If baseline blood pressure is elevated before administering (e.g., >140 mmHg systolic, >90 mmHg diastolic), consider the risks of short term increases in blood pressure and benefit of treatment in patients with treatment- resistant depression (TRD). Do not administer esketamine if an increase in blood pressure or intracranial pressure poses a serious risk. Esketamine is contraindicated in patients with aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels), arteriovenous malformations, or a history of intracerebral hemorrhage.
Liver Disease
Moderate:
esketamine
Esketamine has a moderate potential interaction with Liver Disease.
Esketamine has not been studied in patients with severe hepatic impairment (Child-Pugh class C). Use in this population is not recommended. Additionally, the mean esketamine AUC and t1/2 values were higher in patients with moderate hepatic impairment compared to those with normal hepatic function. Patients with moderate hepatic impairment may need to be monitored for adverse reactions for a longer period of time.
Psychosis
Major:
esketamine
Esketamine has a major potential interaction with Psychosis.
Esketamine can cause dissociative or perceptual changes (including distortion of time, space and illusions), derealization and depersonalization. Patients with psychosis must be carefully assessed before administering esketamine, and treatment should be initiated only if the benefit outweighs the risk. Patients must be monitored by a healthcare provider for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.
Report options
More resources
esketamine
A total of 302 drugs are known to interact with esketamine.
- Esketamine is in the drug class miscellaneous antidepressants.
- Esketamine is used to treat the following conditions:
methoxyflurane
A total of 249 drugs are known to interact with methoxyflurane.
- Methoxyflurane is in the drug class general anesthetics.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.